Influenza vaccine as a coronary intervention for prevention of myocardial infarction.

MacIntyre, CR; Mahimbo, A; Moa, AM; Barnes, M

Influenza vaccine as a coronary intervention for prevention of myocardial infarction.

MacIntyre, CR Mahimbo, A

Moa, AM Barnes, M

Permalink

Publisher:: BMJ PUBLISHING GROUP
Publication Type:: Journal Article
Citation:: Heart, 2016, 102, (24), pp. 1953-1956
Issue Date:: 2016-12-15

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (423.18 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	MacIntyre, CR
dc.contributor.author	Mahimbo, A https://orcid.org/0000-0003-2058-6881
dc.contributor.author	Moa, AM
dc.contributor.author	Barnes, M
dc.date.accessioned	2022-04-19T00:06:17Z
dc.date.available	2016-08-30
dc.date.available	2022-04-19T00:06:17Z
dc.date.issued	2016-12-15
dc.identifier.citation	Heart, 2016, 102, (24), pp. 1953-1956
dc.identifier.issn	1355-6037
dc.identifier.issn	1468-201X
dc.identifier.uri	http://hdl.handle.net/10453/156374
dc.description.abstract	Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Influenza is one of the leading infectious causes of morbidity and mortality globally, and evidence is accumulating that it can precipitate acute myocardial infarction (AMI). This is thought to be due to a range of factors including inflammatory release of cytokines, disruption of atherosclerotic plaques and thrombogenesis, which may acutely occlude a coronary artery. There is a large body of observational and clinical trial evidence that shows that influenza vaccine protects against AMI. Estimates of the efficacy of influenza vaccine in preventing AMI range from 15% to 45%. This is a similar range of efficacy compared with the accepted routine coronary prevention measures such as smoking cessation (32-43%), statins (19-30%) and antihypertensive therapy (17-25%). Influenza vaccine should be considered as an integral part of CVD management and prevention. While it is recommended in many guidelines for patients with CVD, rates of vaccination in risk groups aged <65 years are very low, in the range of 30%. The incorporation of vaccination into routine CVD prevention in patient care requires a clinical practice paradigm change.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	BMJ PUBLISHING GROUP
dc.relation.ispartof	Heart
dc.relation.isbasedon	10.1136/heartjnl-2016-309983
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences
dc.subject.classification	Cardiovascular System & Hematology
dc.subject.mesh	Animals
dc.subject.mesh	Antihypertensive Agents
dc.subject.mesh	Dyslipidemias
dc.subject.mesh	Humans
dc.subject.mesh	Hydroxymethylglutaryl-CoA Reductase Inhibitors
dc.subject.mesh	Hypertension
dc.subject.mesh	Influenza Vaccines
dc.subject.mesh	Influenza, Human
dc.subject.mesh	Myocardial Infarction
dc.subject.mesh	Risk Assessment
dc.subject.mesh	Risk Factors
dc.subject.mesh	Secondary Prevention
dc.subject.mesh	Smoking
dc.subject.mesh	Smoking Cessation
dc.subject.mesh	Smoking Prevention
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Vaccination
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Myocardial Infarction
dc.subject.mesh	Hypertension
dc.subject.mesh	Antihypertensive Agents
dc.subject.mesh	Influenza Vaccines
dc.subject.mesh	Hydroxymethylglutaryl-CoA Reductase Inhibitors
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Vaccination
dc.subject.mesh	Risk Assessment
dc.subject.mesh	Risk Factors
dc.subject.mesh	Smoking
dc.subject.mesh	Smoking Cessation
dc.subject.mesh	Dyslipidemias
dc.subject.mesh	Influenza, Human
dc.subject.mesh	Secondary Prevention
dc.subject.mesh	Smoking Prevention
dc.title	Influenza vaccine as a coronary intervention for prevention of myocardial infarction.
dc.type	Journal Article
utslib.citation.volume	102
utslib.location.activity	England
utslib.for	1102 Cardiorespiratory Medicine and Haematology
utslib.for	1103 Clinical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
utslib.copyright.status	open_access	*
dc.date.updated	2022-04-19T00:06:16Z
pubs.issue	24
pubs.publication-status	Published
pubs.volume	102
utslib.citation.issue	24

Abstract:

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Influenza is one of the leading infectious causes of morbidity and mortality globally, and evidence is accumulating that it can precipitate acute myocardial infarction (AMI). This is thought to be due to a range of factors including inflammatory release of cytokines, disruption of atherosclerotic plaques and thrombogenesis, which may acutely occlude a coronary artery. There is a large body of observational and clinical trial evidence that shows that influenza vaccine protects against AMI. Estimates of the efficacy of influenza vaccine in preventing AMI range from 15% to 45%. This is a similar range of efficacy compared with the accepted routine coronary prevention measures such as smoking cessation (32-43%), statins (19-30%) and antihypertensive therapy (17-25%). Influenza vaccine should be considered as an integral part of CVD management and prevention. While it is recommended in many guidelines for patients with CVD, rates of vaccination in risk groups aged <65 years are very low, in the range of 30%. The incorporation of vaccination into routine CVD prevention in patient care requires a clinical practice paradigm change.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/156374